Previous 10 | Next 10 |
2023-12-12 12:40:26 ET More on Intra-Cellular Therapies The Right Play On Intra-Cellular Therapies Intra-Cellular's Caplyta Is Well On Its Way To Being A Mental Health Blockbuster Intra-Cellular Therapies, Inc. (ITCI) Q3 2023 Earnings Call Transcript Intra-Ce...
Company presents positive results of a pre-specified patient population in Study 403 examining the effects of CAPLYTA ® (lumateperone) in patients experiencing a major depressive episode with anxious distress and mixed features. Company presents preclinical data on ITI-1549, ou...
2023-11-20 11:49:37 ET Summary Intra-Cellular Therapies, Inc. is a mid-cap biopharmaceutical company focused on developing treatments for neuropsychiatric and neurological disorders. The company's commercial asset, Caplyta, has achieved significant sales growth and is an exciting ...
NEW YORK, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will present at the 6th Annual Evercore ISI H...
2023-11-13 05:47:25 ET Summary Intra-Cellular Therapies shows strong financial growth, driven by Caplyta sales, with improved operational efficiency and reduced net losses. Caplyta's success in schizophrenia and bipolar depression, and its potential in Major Depressive Disorder, u...
2023-11-02 15:15:04 ET Intra-Cellular Therapies, Inc. (ITCI) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET Company Participants Juan Sanchez – Head-Investor Relations Sharon Mates – Chairman and Chief Executive Officer Mark Neumann ...
2023-11-02 07:45:01 ET More on Intra-Cellular Therapies Intra-Cellular Therapies: Caplyta's Rise And A Promising Pipeline Intra-Cellular Therapies Q3 2023 Earnings Preview Seeking Alpha’s Quant Rating on Intra-Cellular Therapies Historical earnings dat...
Q3 2023 total revenues increased to $126.2 million , compared to $71.9 million in the same period in 2022 CAPLYTA Q3 2023 net product sales were $125.8 million , compared to $71.9 million for the same period in 2022...
Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...
Intra-Cellular Therapies Inc. (ITCI) is expected to report $-0.59 for Q3 2023
News, Short Squeeze, Breakout and More Instantly...
Intra-Cellular Therapies Inc. Company Name:
ITCI Stock Symbol:
NASDAQ Market:
Intra-Cellular Therapies Inc. Website:
CAPLYTA Q1 2024 net product sales were $144.8 million , compared to $94.7 million for the same period in 2023 , representing a 53% increase CAPLYTA’s strong prescription uptake continues: Q1 2024 CAPLYTA total prescripti...
Aterian Inc. (ATER) is expected to report for Q1 2024 Dorman Products Inc. (DORM) is expected to report $0.82 for Q1 2024 Hillman Solutions Corp. (HLMN) is expected to report $0.08 for Q1 2024 Wake Forest Bancshares, Inc. (WAKE) is expected to report for quarter end 2024-03-31 Inn...
NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the developme...